Novel biologic approaches to hematologic malignancies.
Biologic agents have made a major impact on the treatment of hematologic malignancies and will continue to play a major role as we better understand their function in normal and malignant cell regulation. The examples provided in this chapter are a brief introduction to the potential of these agents. Many have yet to be used in conjunction with current cytotoxic therapy in these diseases, and perhaps combinations will prove even more successful. This possibility provides substantial ground for further investigation and therapy.
Dutcher
J P
JP
Albert Einstein Cancer Center, Montefiore Medical Cancer, Bronx, New York 10467, USA.
Wiernik
P H
PH
D016026:Bone Marrow Transplantation; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use; D007951:Leukemia, Myeloid / Q000628:therapy*; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D009101:Multiple Myeloma / Q000628:therapy*; D009190:Myelodysplastic Syndromes / Q000628:therapy*
D007376:Interleukin-2